Survivors of esophageal cancer need surveillance beyond 5 years after surgery

the ONA take:

A new study focuses on survival outcomes of patients with locally advanced esophageal cancer (LAEC) beyond the 5-year mark.

In this retrospective analysis, researchers reviewed the health records of 355 patients with LAEC who underwent esophagectomy between January 1988 and September 2009.

Most of the patients were men; 52.9% of the group received other treatments as well (ie, chemotherapy, chemoradiotherapy, or radiotherapy before surgery).

Five years after surgery, 140 patients (39%) were still alive and were then followed-up for a median of 41 months. Overall survival (OS) was 86% at 7 years, 70% at 10 years, and 51% at 15 years. Cancer-specific survival (CSS) was 88% at 7 years and 84% at 10 years.

Almost one-third of patients who developed recurrent disease were still alive 10 years after their first surgery, with most recurrences occurring within the first 5 years.

The researchers report, “The annualized risk of recurrence was 1.4% per year until year 10, when CSS reaches its plateau.”

Although esophageal cancer survivors’ risks of disease recurrence, new primary cancers, or chronic pulmonary disease are low, long-term surveillance should be consider for these patients.

Gefitinib may be effective to treat esophageal cancer in some patients
A new study focuses on survival outcomes of patients with locally advanced esophageal cancer (LAEC) beyond the 5-year mark.
Patients with esophageal cancer who survive 5 years after undergoing surgery might breathe a sigh of relief and become complacent about continued monitoring.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs